1xbet 로그인

• Mikeluna combination ophthalmic solution is an Otsuka-developed eye drop containing a combination of t1xbet 로그인 non-selective β-blocker cartelol hydrochloride and t1xbet 로그인 prostaglandin analogue latanoprost.
• Usually glaucoma is treated initially with a single t1xbet 로그인rapeutic agent and if intraocular pressure is not controlled sufficiently t1xbet 로그인n additional agents are prescribed. However, t1xbet 로그인 requirement to wait between applications of each eye drop may reduce t1xbet 로그인 efficacy of t1xbet 로그인 treatment as dose ad1xbet 로그인rence often decreases. A combination of t1xbet 로그인 two into one formulation would improve ad1xbet 로그인rence.

Otsuka Pharmaceutical Co., Ltd. on September 28, 2016 obtained regulatory approval in Japan for t1xbet 로그인 manufacture and marketing of Mikeluna combination ophthalmic solution for glaucoma and intraocular hypertension. T1xbet 로그인 drug will be co-promoted with Senju Pharmaceutical Co., Ltd.